Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Hussain SP. Pancreatic cancer: current progress and future challenges. Int J Biol Sci. 2016;12(3):270–272.
   PubMed Web of Science ®Google Scholar
• Daniel Ansari BT, Andersson B, Holmquist F, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12(16):1929–1946.
   PubMed Web of Science ®Google Scholar
• Li S, Xu HX, Wu CT, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019;22(1):15–36.
   PubMed Web of Science ®Google Scholar
• Krepline A, Tsai S. Has personalized medicine for pancreatic cancer arrived? Adv Surg. 2019;53:103–115.
   PubMedGoogle Scholar
• Johansson H, Andersson R, Bauden M, et al. Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol. 2016;22(43):9457–9476.
   PubMed Web of Science ®Google Scholar
• Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232–1243.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513–5518.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. ftGTDoUatP: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-Paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Tempero MA. NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 2019;17(5.5):603–605.
   PubMed Web of Science ®Google Scholar
• Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol. 2016;10(3):301–316.
   PubMed Web of Science ®Google Scholar
• He G, Jiang Y, Zhang B, et al. The effect of HIF-1α on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Asia Pac J Clin Nutr. 2014;23(1):174–180.
   PubMed Web of Science ®Google Scholar
• Li D, Duell EJ, Yu K, et al. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis. 2012;33(7):1384–1390.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, van der Borden CL, Frampton AE, et al. Never let it go: stopping key mechanisms underlying metastasis to fight pancreatic cancer. Semin Cancer Biol. 2017;44:43–59.
   PubMed Web of Science ®Google Scholar
• Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol. 2017;116(1):25–34.
   PubMed Web of Science ®Google Scholar
• Reccia I, Kumar J, Habib N, et al. The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology. Med Oncol. 2018;35(12):151.
   PubMed Web of Science ®Google Scholar
• Ruarus AH, Vroomen L, Geboers B, et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, Single-Arm, phase II study. Radiology. 2020;294(1):212–220.
   PubMed Web of Science ®Google Scholar
• Tasu JP, Vesselle G, Herpe G, et al. Irreversible electroporation for locally advanced pancreatic cancer. Diagn Interv Imaging. 2016;97(12):1297–1304.
   PubMed Web of Science ®Google Scholar
• Marinova M, Strunk HM, Rauch M, et al. High-intensity focused ultrasound (HIFU) for tumor pain relief in inoperable pancreatic cancer: evaluation with the pain sensation scale (SES). Schmerz. 2017;31(1):31–39.
   PubMed Web of Science ®Google Scholar
• Strunk HM, Lutzow C, Henseler J, et al. Mesenteric vessel patency following HIFU therapy in patients with locally invasive pancreatic cancer. Ultraschall Med. 2018;39(6):650–658.
   PubMed Web of Science ®Google Scholar
• Marinova M, Huxold HC, Henseler J, et al. Clinical effectiveness and potential survival benefit of US-guided high-intensity focused ultrasound therapy in patients with advanced-stage pancreatic cancer. Ultraschall Med. 2019;40(5):625–637.
   PubMed Web of Science ®Google Scholar
• Marinova M, Wilhelm-Buchstab T, Strunk H. Advanced pancreatic cancer: high-Intensity focused ultrasound (HIFU) and other local ablative therapies. Rofo. 2019;191(3):216–227.
   PubMedGoogle Scholar
• Cheung MW, Vijayakumar R. A guide to conducting a meta-analysis. Neuropsychol Rev. 2016;26(2):121–128.
   PubMed Web of Science ®Google Scholar
• David Moher LS, Clarke M, Ghersi D, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Devereaux PJ, Wetterslev J, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009;38(1):276–286.
   PubMed Web of Science ®Google Scholar
• Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75.
   PubMed Web of Science ®Google Scholar
• Janice M, Pogue M, Yusuf S. FRCPC: cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Contr Clin Trials. 1997;18(6):580–593.
   PubMedGoogle Scholar
• Zeng Qingdong LL, Xiuguo Z, Bin L, et al. Clinical study of high intensity focused ultrasound combined with genze in the treatment of advanced pancreatic cancer. Chinese J Hepatobil Surg. 2006;12(11):748–750.
   Google Scholar
• Zhang Tao ZD, Wei L, Guojing W, et al. Clinical effect of high intensity focused ultrasound combined with gemcitabine in the treatment of unresectable pancreatic cancer. Compr Clin Pract China. 2012;28(8):793–796.
   Google Scholar
• Yu Z, Yongshuo J, Hong Z, et al. Efficacy of intensive focused ultrasound in the treatment of senile pancreatic cancer. Geriatrics Health Care. 2013;19(5):308–311.
   Google Scholar
• Lv W, Yan T, Wang G, et al. High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma. Ther Clin Risk Manag. 2016;12:687–691.
   PubMed Web of Science ®Google Scholar
• Li X, Wang K, Zheng L, et al. Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine. Am J Cancer Res. 2016;6(1):84–90.
   PubMed Web of Science ®Google Scholar
• Zhiqiang G, Gong Z, Yang W, et al. Application of HIFU combined with gemcitabine in the treatment of advanced pancreatic cancer. J Hepatobil Pancreatic Surg. 2018;30(2):98–101.
   Google Scholar
• Ning Z, Xie J, Chen Q, et al. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. OTT. 2019;12:1021–1029.
   Web of Science ®Google Scholar
• Lynn JG, Zwemer RL, Chick AJ, et al. A new method for the generation and use of focused ultrasound in experimental BIOLOGY. J Gen Physiol. 1942;26(2):179–193.
   PubMedGoogle Scholar
• Van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M, et al. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017;66(2):247–258.
   PubMed Web of Science ®Google Scholar
• Xiao W, Jingzhong S. High-intensity focused ultrasound in patients with late-stage pancreatic carcinoma. Chinese. Chinese. 2002;115(9):1332–1335.
   Google Scholar
• Strunk HM, Henseler J, Rauch M, et al. Clinical use of High-Intensity focused ultrasound (HIFU) for tumor and pain reduction in advanced pancreatic cancer. Rofo. 2016;188(7):662–670.
   PubMedGoogle Scholar
• Wang K, Chen Z, Meng Z, et al. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia. 2011;27(2):101–107.
   PubMed Web of Science ®Google Scholar
• Wu F, Wang Z-B, Zhu H, et al. Feasibility of US-guided High-Intensity focused ultrasound treatment in patients with advanced pancreatic cancer: initial experience. Radiology. 2005;236(3):1034–1040.
   PubMed Web of Science ®Google Scholar
• Zhao H, Yang G, Wang D, et al. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs. 2010;21(4):447–452.
   PubMed Web of Science ®Google Scholar
• Sung HY, Jung SE, Cho SH, et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas. 2011;40(7):1080–1086.
   PubMed Web of Science ®Google Scholar
• Shen H, Xiaoye H, Tianzhou C. Concurrent chemotherapy and high intensity focused ultrasound treatment for patients with local advanced pancreatic cancer or metastatic pancreatic cancer: a retrospective study. J Clin Oncol. 2014;32(15):e15242.
   Web of Science ®Google Scholar